All PlansCoverageMedium impact
BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their medical policy for BCR-ABL1 testing used in diagnosing and monitoring chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). This policy covers molecular testing for diagnosis confirmation, treatment monitoring, and drug resistance identification for Philadelphia chromosome-positive leukemias.
Action Required
Review current BCR-ABL1 testing orders and documentation practices for CML and ALL patients. Ensure proper medical necessity documentation is included when ordering qualitative BCR-ABL1 fusion gene testing for CML diagnosis confirmation, quantitative transcript testing for treatment monitoring, and resistance variant analysis when there is inadequate response to tyrosine kinase inhibitors. Update clinical staff on the specific testing criteria outlined in the policy.